Dr. Byram Bridle Warns About Flaws in Vaccine Development

laims research-grade plasmid elements—normally used only in early lab work—were carried forward into vaccine development.

Suggests rapid timelines during Operation Warp Speed may have contributed to oversights.

Argues certain genetic components acceptable in preclinical research should not appear in a regulated medical product.

Raises concerns about DNA removal efficiency, claiming manufacturers lacked experience with synthetic materials.

Says the issue reflects broader problems in pharmaceutical oversight and regulatory transparency.